Bimonthly administered long-acting cabotegravir and rilpivirine are highly effective and well-tolerated in people with human immunodeficiency virus above 65 years

Older people with HIV (PWH) may benefit from long-acting cabotegravir/rilpivirine (LA-CAB/RPV), a population underrepresented in trials and observational cohorts. In the GEPPO cohort, 135 PWH >65 years of age received bimonthly LA-CAB/RPV. After 17.4 months, virological suppression (HIV-RNA <50 copies/mL) was maintained in all, while 15 participants discontinued them (11.1%, 10% in the first 12 months): 1 participant with isolated HbCAb at baseline showed a late HBV reactivation (19.4 months after starting). These findings support LA-CAB/RPV's efficacy and tolerability in older PWH.